Biomarker Testing in Metastatic Colorectal Cancer
Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate
May 11th 2023Dr Haffner explains distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prostate carcinoma, and the challenges that arise when diagnosing and treating patients with this rare disease.
Effective Detection of MRD May Support Earlier Implementation of ctDNA Testing in CRC
April 6th 2023Stacey A. Cohen, MD, discusses the advantages and limitations of ctDNA as a biomarker for detecting minimal residual disease , real-world data on the relationship between fluctuating cfDNA levels and ctDNA detection, and how implementing ctDNA testing earlier to identify minimal residual disease could serve as a prognostic tool in clinical practice.
First-line Avelumab Maintenance Under Real-world Evaluation in Metastatic Urothelial Carcinoma
The baseline characteristics, treatment patterns, and responses to first-line platinum-based chemotherapy for patients with locally advanced or metastatic urothelial carcinoma receiving avelumab maintenance therapy were consistent with responses to usual therapy paradigms in the first-line induction setting.
Researcher Highlights Need for Improved Understanding of Prostate Basal Cell Carcinoma
Basal cell carcinoma of the prostate is a rare variant of prostate cancer so uncommon that few physicians will ever treat the disease in their careers. Only 100 or so patients have been identified in the literature compared with more than 1 million diagnoses every year for adenocarcinoma.